T. Rowe Price Associates
MXCT icon

T. Rowe Price Associates’s MaxCyte MXCT Stock Holding History

T. Rowe Price Associates’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,537
Closed -$37K – 3302
2026
Q1 		$37K Hold
51,537
– – ﹤0.01% 3086
2025
Q4 		$80K Hold
51,537
– – ﹤0.01% 2975
2025
Q3 		$82K Hold
51,537
– – ﹤0.01% 2958
2025
Q2 		$113K Buy
51,537
+6,388
+14% +$15.5K ﹤0.01% 2872
2025
Q1 		$124K Buy
45,149
+2,793
+7% +$11K ﹤0.01% 2779
2024
Q4 		$177K Buy
42,356
+8,951
+27% +$33.8K ﹤0.01% 2731
2024
Q3 		$130K Hold
33,405
– – ﹤0.01% 2769
2024
Q2 		$131K Buy
33,405
+8,206
+33% +$35.3K ﹤0.01% 2703
2024
Q1 		$106K Buy
25,199
+4,320
+21% +$20.3K ﹤0.01% 2771
2023
Q4 		$99K Buy
20,879
+2,082
+11% +$8.11K ﹤0.01% 2719
2023
Q3 		$59K Buy
18,797
+674
+4% +$2.71K ﹤0.01% 2756
2023
Q2 		$84K Buy
18,123
+1,494
+9% +$6.87K ﹤0.01% 2725
2023
Q1 		$83K Buy
16,629
+1,455
+10% +$7.17K ﹤0.01% 2717
2022
Q4 		$83K Buy
15,174
+1,681
+12% +$10.3K ﹤0.01% 2749
2022
Q3 		$88K Buy
+13,493
New +$75.3K ﹤0.01% 2753
2022
Q2 		– Sell
-37,018
Closed -$259K – 2996
2022
Q1 		$259K Sell
37,018
-519,798
-93% -$3.55M ﹤0.01% 2609
2021
Q4 		$5.67M Buy
556,816
+55,494
+11% +$596K ﹤0.01% 1480
2021
Q3 		$6.12M Buy
+501,322
New +$7.56M ﹤0.01% 1489

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

T. Rowe Price Associates's MXCT Position: Q2 2026 in Review

T. Rowe Price Associates sold out of MaxCyte (MXCT) in Q2 2026, closing a stake of 51,537 shares — an estimated $37K sold.

T. Rowe Price Associates first reported a position in MXCT in Q3 2021 and held it in 18 quarters. The position peaked at $6.12M in Q3 2021. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • T. Rowe Price Associates reported no remaining MaxCyte position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 51,537 MaxCyte shares in Q2 2026, an estimated $37K.
  • T. Rowe Price Associates first reported a position in MaxCyte in Q3 2021 and held it in 18 quarters.
  • T. Rowe Price Associates's MaxCyte position peaked at $6.12M in Q3 2021.
  • 122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.